查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1970927

用于血液检测的运动医学生物标记市场－全球产业规模、份额、趋势、机会、预测：按类型、地区和竞争格局划分，2021-2031年

Blood-based Biomarker For Sports Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球运动医学血液生物标记市场预计将从 2025 年的 8.1312 亿美元成长到 2031 年的 11.6391 亿美元，复合年增长率为 6.16%。

这些生物标记分析血液中的生物指标，作为专业的诊断工具，用于测量生理压力、评估伤害严重程度并指南运动员的復健策略。市场成长的关键驱动因素是运动相关损伤发生率的上升以及对客观数据以缩短復原时间的需求日益增长。这些因素要求在标准身体检查之外，需要更精确的体内监测能力，这反映出产业有长期而非暂时的需求。例如，根据美国国家安全委员会的报告，到2024年，约有440万人将因运动和休閒器材相关损伤而需要急诊治疗。这凸显了迫切需要有效的诊断方法来支持安全重返赛场的决策。

市场概览
预测期 2027-2031
市场规模：2025年 8.1312亿美元
市场规模：2031年 1,163,910,000 美元
复合年增长率：2026-2031年 6.16%
成长最快的细分市场 尿素
最大的市场 北美洲

然而，市场扩张的一大障碍是频繁血液检测和分析的高成本。小规模体育组织和业余联赛往往缺乏资金来承担定期生物标记筛检所需的物流和检测费用。这种经济限制使得这些诊断方案的应用范围主要局限于精英职业队，从而为更广泛的运动员群体设置了很高的准入门槛。

市场驱动因素

就地检验技术的进步有效地降低了市场准入门槛，将诊断能力从远端检查室直接转移到了体育场边。这种转变使得医护人员能够在撞击后立即量化脑损伤指标，例如泛素C端水解酵素L1 (UCH-L1) 和胶质纤维酸性蛋白 (GFAP)，无需等待数小时才能获得结果。例如，2025年5月，雅培公司宣布在其所有MotoAmerica赛事中部署手持式i-STAT TBI检测仪，该检测仪可在15分钟内提供检查室级别的精确结果，以促进对脑震荡的即时评估。随着各联盟加强安全措施，这种精准的诊断变得越来越重要。美国国家美式足球联盟 (NFL) 报告称，2024年赛季脑震盪发生率下降了17%，凸显了对伤病管理策略的严格重视。

此外，将人工智慧融入生物标记分析正在加速市场成长，因为它能够准确解读复杂的生物数据，并为每位运动员提供个人化护理。人工智慧演算法可以长期监测血液指标，检测细微的生理异常，从而製定客製化的恢復通讯协定，最大限度地提高运动员的出场率。这种潜力正在推动该领域的大规模投资；例如，爱尔兰企业局 (Enterprise Ireland) 在 2025 年 12 月报告称，Orreco 已筹集 400 万美元，用于扩展其人工智慧驱动的运动表现智慧平台。该平台将生物标记数据与外部负荷指标关联起来，以降低受伤风险，使团队能够就运动员重返赛场做出客观、数据驱动的决策。

市场挑战

频繁的血液检测和分析成本高昂，构成了限制市场扩充性的重大经济障碍。与只需一次性硬体投入的非侵入性监测工具不同，基于血液的生物标记分析涉及持续的支出，例如采血专家的工资、低温运输物流以及专业检查室分析的费用。这些营运需求导致每次检测的高成本，对于绝大多数体育组织而言，在经济上难以负担。因此，这些诊断方案的应用主要局限于拥有雄厚医疗预算的精英职业球队，难以渗透到预算紧张的业余和大学运动领域。

这种营运上的差异也反映在全球侵入性检测方法的普及率上。根据世界反兴奋剂机构（WADA）统计，2024年全球经认证的实验室仅分析了31,003份血液和干血斑检体，仅占运动员生物检体总数的一小部分。即使在国际体育赛事监管最严格的级别，如此有限的检体量也凸显了血液检测在后勤和经济方面固有的障碍。因此，血液检测市场难以突破顶级竞技运动的限制，而常规内部监测所需的投资对于普通市场而言仍然难以承受。

市场趋势

面向消费者的运动员血液检测服务的兴起，正从根本上改变着市场的可及性，使业余和半职业运动员也能享受到专业级的诊断服务。以往只有拥有专业医疗团队的精英机构才能提供的全面血液分析，如今透过绕过传统医疗安全隔离网闸的订阅模式，健身爱好者也能直接获得这项服务。这一趋势推动了检测量的增加，生物标记分析被整合到标准的健身会员服务中，使用户能够自主追踪自身的生理基准。例如，2024年5月，InsideTracker与FITNESS SF合作，将血液生物标记分析直接整合到会员计画中，为超过35,000名客户提供每年两次的血液检测，以优化训练和恢復。

此外，微创毛细血管采血技术的开发消除了传统静脉穿刺带来的许多后勤障碍，从而能够进行高频监测，这对于长期追踪运动员的健康状况至关重要。与需要专业采血技术人员的侵入性针刺不同，这种新型微量采血装置使运动员即使在偏远地区也能准确地从上臂或指尖自行采集样本。这项创新对于推广运动表现提升和反兴奋剂项目至关重要，因为在这些项目中，后勤便利性和运动员的舒适度是重中之重。为了说明这项技术的广泛应用，Tasso公司于2024年7月宣布，其毛细血管采血技术将在包括2024年巴黎奥运在内的重大国际赛事中得到应用，这将有助于简化检体采集流程，并提升运动员的体验。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：运动医学血液检测生物标记的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按类型（CK、肌红蛋白、乳酸、白血球计数、尿素、CRP、脂质和蛋白质氢过氧化物、IL-6、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美运动医学血液检测生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲运动医学血液检测生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区运动医学血液检测生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲运动医学血液检测生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲运动医学血液检测生物标记市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球运动医学血液检测生物标记市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Abbott Laboratories
  • BIOMeRIEUX
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories Inc.
  • Siemens Healthineers AG
  • RayBiotech, Inc
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc
  • Beckman Coulter, Inc.
  • Randox Laboratories Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27717

The Global Blood-based Biomarker For Sports Medicine Market is projected to increase from USD 813.12 Million in 2025 to USD 1163.91 Million by 2031, registering a CAGR of 6.16%. These biomarkers function as specialized diagnostic instruments that examine biological indicators within the blood to measure physiological stress, assess injury severity, and guide recovery strategies for athletes. The primary factors driving market growth are the rising incidence of sports-related injuries and the increasing demand for objective data to shorten recovery timelines. These drivers necessitate accurate internal monitoring capabilities that surpass standard physical evaluations and represent permanent industry needs rather than temporary shifts. For example, the National Safety Council reported that in 2024, approximately 4.4 million individuals were treated in emergency departments for injuries involving sports and recreational equipment, underscoring the urgent need for effective diagnostics to support safe return-to-play decisions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 813.12 Million
Market Size 2031USD 1163.91 Million
CAGR 2026-20316.16%
Fastest Growing SegmentUrea
Largest MarketNorth America

However, a significant obstacle impeding market expansion is the high cost associated with implementing frequent blood profiling and analysis. Smaller sports organizations and amateur leagues often lack the financial means to cover the logistical and laboratory expenses necessary for routine biomarker screening. This economic limitation restricts the scalability of these diagnostic solutions largely to elite professional franchises, creating a substantial barrier to entry for the broader athletic population.

Market Driver

Technological advancements in point-of-care testing are effectively lowering entry barriers in the market by relocating diagnostic capabilities from remote laboratories directly to the athletic sideline. This transition allows medical staff to instantly quantify brain injury indicators, such as ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), immediately following a collision instead of waiting hours for results. For instance, in May 2025, Abbott announced that its handheld i-STAT TBI test, which provides lab-quality results within 15 minutes, was deployed at all MotoAmerica races to facilitate real-time concussion assessment. Such precise diagnostics are becoming increasingly vital as leagues strengthen safety protocols; the NFL reported a 17% decrease in concussions during the 2024 season, highlighting a rigorous focus on injury management strategies.

Furthermore, the integration of artificial intelligence into biomarker analysis is accelerating market growth by enabling the precise interpretation of complex biological data for personalized athlete care. AI algorithms can examine longitudinal blood profiles to detect subtle physiological deviations, allowing for customized recovery protocols that optimize player availability. This potential has triggered significant investment in the sector; for example, Enterprise Ireland reported in December 2025 that Orreco raised $4 million to scale its AI-powered performance intelligence platform. This platform correlates biomarker data with external load metrics to reduce injury risks, collectively empowering teams to make objective, data-driven decisions regarding an athlete's return to play.

Market Challenge

The prohibitive cost associated with establishing frequent blood profiling and analysis creates a severe economic barrier that limits the scalability of the market. Unlike non-invasive monitoring tools that involve a one-time hardware expense, blood-based biomarker analysis requires recurring expenditures for phlebotomy professionals, cold-chain logistics, and specialized laboratory assays. These operational demands result in a high cost-per-test structure that is financially unsustainable for the majority of athletic organizations. Consequently, the adoption of these diagnostic solutions is largely restricted to elite professional franchises with substantial medical budgets, preventing penetration into the wider amateur and collegiate sports sectors where financial resources are strictly allocated.

This operational disparity is evident in the global utilization rates of invasive testing methods. According to the World Anti-Doping Agency, accredited laboratories analyzed 31,003 blood and dried blood spot samples worldwide in 2024, a figure representing only a small fraction of the total biological samples collected from athletes. This limited volume, even within the most highly regulated tier of international sports, underscores the logistical and financial friction inherent in blood-based diagnostics. As a result, the market struggles to expand beyond the top tier of competitive sports, as the requisite investment for routine internal monitoring remains out of reach for the mass market.

Market Trends

The rise of Direct-to-Consumer (DTC) athlete blood testing services is fundamentally reshaping market accessibility by democratizing professional-grade diagnostics for the amateur and semi-professional sectors. Previously the exclusive domain of elite franchises with dedicated medical staff, comprehensive blood profiling is now directly available to fitness enthusiasts through subscription-based models that bypass traditional clinical gatekeepers. This trend drives volume growth by integrating biomarker analysis into standard fitness memberships, allowing individuals to track physiological baselines independently. For example, in May 2024, InsideTracker partnered with FITNESS SF to integrate its blood biomarker analytics directly into membership tiers, providing over 35,000 clients with biannual blood testing to optimize training and recovery.

Additionally, the development of minimally invasive capillary blood sampling technologies is removing the logistical friction of traditional venipuncture, thereby enabling the high-frequency monitoring essential for longitudinal athlete tracking. Unlike invasive needle draws that require phlebotomy professionals, novel microsampling devices allow athletes to self-collect precise samples from the upper arm or fingertip in remote settings. This innovation is critical for scaling performance and anti-doping programs where logistical ease and athlete comfort are paramount. Demonstrating this widespread acceptance, Tasso announced in July 2024 that its capillary blood collection technology was deployed at major international events, including the Paris 2024 Olympic Games, to streamline sample collection processes and enhance the athlete experience.

Key Market Players

  • Abbott Laboratories
  • BIOMeRIEUX
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories Inc.
  • Siemens Healthineers AG
  • RayBiotech, Inc
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc
  • Beckman Coulter, Inc.
  • Randox Laboratories Ltd.

Report Scope

In this report, the Global Blood-based Biomarker For Sports Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Blood-based Biomarker For Sports Medicine Market, By Type

  • CK
  • Myoglobin
  • Lactate
  • WBC
  • Urea
  • CRP
  • Lipid and Protein Hydroperoxides
  • IL-6
  • Others

Blood-based Biomarker For Sports Medicine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood-based Biomarker For Sports Medicine Market.

Available Customizations:

Global Blood-based Biomarker For Sports Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Blood-based Biomarker For Sports Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (CK, Myoglobin, Lactate, WBC, Urea, CRP, Lipid and Protein Hydroperoxides, IL-6, Others)
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America Blood-based Biomarker For Sports Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Blood-based Biomarker For Sports Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
    • 6.3.2. Canada Blood-based Biomarker For Sports Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
    • 6.3.3. Mexico Blood-based Biomarker For Sports Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type

7. Europe Blood-based Biomarker For Sports Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
    • 7.3.2. France Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
    • 7.3.3. United Kingdom Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
    • 7.3.4. Italy Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
    • 7.3.5. Spain Blood-based Biomarker For Sports Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type

8. Asia Pacific Blood-based Biomarker For Sports Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
    • 8.3.2. India Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
    • 8.3.3. Japan Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
    • 8.3.4. South Korea Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
    • 8.3.5. Australia Blood-based Biomarker For Sports Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type

9. Middle East & Africa Blood-based Biomarker For Sports Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Blood-based Biomarker For Sports Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
    • 9.3.2. UAE Blood-based Biomarker For Sports Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
    • 9.3.3. South Africa Blood-based Biomarker For Sports Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type

10. South America Blood-based Biomarker For Sports Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Blood-based Biomarker For Sports Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
    • 10.3.2. Colombia Blood-based Biomarker For Sports Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
    • 10.3.3. Argentina Blood-based Biomarker For Sports Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Blood-based Biomarker For Sports Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BIOMeRIEUX
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. ARUP Laboratories Inc.
  • 15.5. Siemens Healthineers AG
  • 15.6. RayBiotech, Inc
  • 15.7. Thermo Fisher Scientific, Inc.
  • 15.8. Bio-Rad Laboratories, Inc
  • 15.9. Beckman Coulter, Inc.
  • 15.10. Randox Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer